Skip to content
value.today
GlycoMimetics Inc. logo

GlycoMimetics Inc.

Total raised
$54 M
2 rounds on record
Latest round
$39 M
Oct 2009
First round on record
Jul 2008
Today
Went public
See the company page

GlycoMimetics Inc. is listed today as Crescent Biopharma, Inc.: market value, financials and filings are on its company page.

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of GlycoMimetics Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2009$39 MNo. 2$10 to $50 million

GlycoMimetics Inc.: Raise no. 2, Oct 2009

Investors in this round

15 investors had bought by the notice of Oct 27, 2010: 15 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for GlycoMimetics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$39 M of $50 M offered; $11 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, securities to be acquired by exercising them, other: Series A-1 Convertible Preferred Stock and underlying common stock upon conversion.
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$38,413 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Helen Thackray · Executive Officer
  • John Magnani · Executive Officer, Director
  • Rachel King · Executive Officer, Director
  • Franklin James Top · Director
  • John James Baldwin · Director
  • M. James Barrett · Director
  • Michael James Henos · Director
  • William James Gust · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “The total amount sold is $38,979,412.47, based on purchase price of $1.2686 per share.”

Signed by Rachel K. King, Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Oct 27, 2010. Read the notice at the SEC.

equitySEC
Jul 2008$15 MNo. 1$10 to $50 million

GlycoMimetics Inc.: Raise no. 1, Jul 2008

Investors in this round

10 investors had bought by the notice of Nov 4, 2009: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for GlycoMimetics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$15 M of $15 M offered
Smallest investment taken
no minimum stated
What was sold
equity, debt, options or other rights to buy securities, securities to be acquired by exercising them, other: Notes convertible into Series A-1 Preferred Stock; warrants to purchase 2,032,858 shares of common stock.
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Helen Thackray · Executive Officer
  • John Magnani · Executive Officer, Director
  • Rachel King · Executive Officer, Director
  • Franklin James Top · Director
  • John James Baldwin · Director
  • M. James Barrett · Director
  • Michael James Henos · Director
  • William James Gust · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Reflects approximate aggregate principal amount of Notes at the time of issuance.”

Signed by Rachel K. King, Chief Executive Officer. Source: SEC Form D, newest notice filed Nov 4, 2009. Read the notice at the SEC.

equity, debt, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company Crescent Biopharma, Inc., its revenue in fiscal 2025 came from these business segments: Reportable $10.84 million (100%).

    Annual report (SEC XBRL) · Dec 2025

  • GlycoMimetics Inc. chose not to state its revenue in its newest notice of a funding round (Oct 2010).

    SEC Form D · Oct 2010

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Oct 2010

Products and services#

No products or services of GlycoMimetics Inc. are on record.

Investors#

8 named in official filings. Open an investor to see everything it has backed.

Investors in GlycoMimetics Inc.
InvestorKindAmountRoundRoleSource
Fairmount Funds Management LLCFund or asset managernot statednot statedHeld Series A preferred stock, 10% owner, director (Form 3, 2025)SEC Form 3
Fairmount Healthcare Fund II L.P.Fund or asset managernot statednot statedHeld Series A preferred stock, 10% owner, director (Form 3, 2025)SEC Form 3
John L. MagnaniPersonnot statednot statedHeld Series A-1 preferred stock, director (Form 3, 2014)SEC Form 3
NEA 13 GP, LtdCompanynot statednot statedHeld Series A-1 preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Nea Partners 10 L.P.Fund or asset managernot statednot statedHeld Series A-1 preferred stock, 10% owner (Form 3, 2014)SEC Form 3
NEA Partners 13, Limited PartnershipFund or asset managernot statednot statedHeld Series A-1 preferred stock, 10% owner (Form 3, 2014)SEC Form 3
New Enterprise Associates 10 L.P.Fund or asset managernot statednot statedHeld Series A-1 preferred stock, 10% owner (Form 3, 2014)SEC Form 3
New Enterprise Associates 13 LPFund or asset managernot statednot statedHeld Series A-1 preferred stock, 10% owner (Form 3, 2014)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 15 investors.

Largest shareholders today

Institutions holding Crescent Biopharma, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by GlycoMimetics Inc.
NameRoleNamed in
Helen ThackrayExecutive officerOct 2010
John MagnaniExecutive officerOct 2010
Rachel KingExecutive officerOct 2010
Franklin James TopDirectorOct 2010
John James BaldwinDirectorOct 2010
John MagnaniDirectorOct 2010
M. James BarrettDirectorOct 2010
Michael James HenosDirectorOct 2010
Rachel KingDirectorOct 2010
William James GustDirectorOct 2010

Went public since 2014. Its SEC number is that of a company listed on a stock exchange.